• Paul B. Chapman, MD

    Clinical Director
    Memorial Sloan Kettering Cancer Center

    Professor of Medicine
    Weill Cornell Medical College

    Dr. Paul B. Chapman is currently Clinical Director of Melanoma and Attending Physician in the Department of Medicine at Memorial Sloan Kettering Cancer Center. He is also Professor of Medicine at Weill Cornell Medical College. He graduated from Cornell University Medical College, completed internship and residency training in Internal Medicine at the University of Chicago, and did his Medical Oncology fellowship at Memorial Sloan Kettering. He is board-certified in Internal Medicine and Medical Oncology and has spent his career working on melanoma.

    He was in the laboratory of Alan Houghton and focused initially on immunotherapy of melanoma. He conducted clinical and laboratory research on the question of immune recognition of melanoma. This included developing a vaccine against GD3 ganglioside and conducting pre-clinical and clinical studies that culminated in an international, randomized phase III trial. Recently his clinical research has also focused on inhibitors of kinases that are mutated or otherwise critical for melanoma growth. He was the Principal Investigator for the phase III randomized trial that led to FDA approval of vemurafenib, the first BRAF inhibitors for melanoma. He has also been a co-author on several checkpoint inhibitor trials including combination trials with ipilimumab and nivolumab. His current work has expanded to focus on targeting melanoma metabolism as a therapeutic strategy.

    He is a peer reviewer for major oncology journals, is an Associate editor for Clinical Cancer Research, and has been on the scientific advisory board for MRF starting in 2004. He has over 150 publications in melanoma.
This website uses cookies to ensure you get the best experience on our website. For more information on the cookies we use, please reference our Privacy Policy.